We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Natural anthraquinone compound emodin as a novel inhibitor of aurora A kinase: A pilot study.
- Authors
Wu, Fen‐Lan; Chu, Pei‐Yi; Chen, Guan‐Yu; Wang, Ke; Hsu, Wei‐Yu; Ahmed, Azaj; Ma, Wen‐Lung; Cheng, Wei‐Chung; Wu, Yang‐Chang; Yang, Juan‐Cheng
- Abstract
Aurora kinase A (AURKA) carries out an essential role in proliferation and involves in cisplatin resistance in various cancer cells. Overexpression of AURKA is associated with the poor prognosis of cancer patients. Thus, AURKA has been considered as a target for cancer therapy. Developing AURKA inhibitors became an important issue in cancer therapy. A natural compound emodin mainly extracted from rhubarbs possesses anti‐cancer properties. However, the effect of emodin on AURKA has never been investigated. In the present study, molecular docking analysis indicated that emodin interacts with AURKA protein active site. We also found nine emodin analogues from Key Organic database by using ChemBioFinder software. Among that, one analogue 8L‐902 showed a similar anti‐cancer effect as emodin. The bindings of emodin and 8L‐902 on AURKA protein were confirmed by cellular thermal shift assay. Furthermore, emodin inhibited the AURKA kinase activity in vitro and enhanced the cisplatin‐DNA adduct level in a resistant ovarian cancer cell line. It seems that emodin may have the potential to inhibit cancer cell growth and enhance cisplatin therapy in cancer with resistance. Collectively, our finding reveals a novel AURKA inhibitor, emodin, which may be vulnerable to ovarian cancer therapy in the future.
- Subjects
EMODIN; AURORA kinases; ANTHRAQUINONES; CANCER cell growth; KINASE inhibitors; CANCER prognosis
- Publication
Chemical Biology & Drug Design, 2022, Vol 99, Issue 1, p126
- ISSN
1747-0277
- Publication type
Article
- DOI
10.1111/cbdd.13938